Company news: EvaluatePharma and Citeline

Share this article:

Years after generic competition begins eroding Lipitor revenues (and RA biologic Humira overtakes it as the world's biggest selling drug), Pfizer will still be the industry's sales leader, but Sanofi and Novartis will run closely behind, according to EvaluatePharma's World Preview 2016. EvaluatePharma forecasts all three companies to have prescription drug sales in the neighborhood of $50 billion by 2016. Sanofi's outlook has been boosted by its $20-billion acquisition of Genzyme, predicted growth in emerging markets and vaccines business, notes EvaluatePharma, while prospects for Novartis' pharmaceutical business have been rosier since approvals for MS pill Gilenya and Tasigna, a follow-on product to leukemia blockbuster Gleevec.

The number of drugs entering Phase III trials increased by 13% vs. 2010, the largest real-term improvement since 1995, reported drug intel firm Citeline. Its 2011 Annual Review of Trends in Pharmaceutical R&D also shows certain anticancer agents held their ground and still dominate the top two therapeutic categories by number of products currently in development (a combined 2,261). Both vaccines/anti-infectives and analgesics moved up a spot to third and fourth place, respectively, in the ranking, while antidiabetics dropped from third to fifth, after that pipeline thinned from 536 products to 507, a 6% decline.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.